Geistlich Pharma
Reinhart Seibl is a seasoned professional in Regulatory Affairs with extensive experience in the medical device and pharmaceutical industries. Currently serving as Director of Regulatory Affairs at Geistlich Pharma AG since January 2019, Reinhart has previously held pivotal roles at Zimmer Biomet, where responsibilities included managing regulatory support for various global operations and leading teams overseeing regulatory compliance across multiple markets. Reinhart's earlier experience at Institut Straumann AG involved global registrations and project management for regenerative products, while initial research work at ETH Zürich culminated in a PhD focusing on immunology. Reinhart holds a Master of Science degree in Biology from the University of Zurich.
This person is not in any offices
Geistlich Pharma
1 followers
Geistlich Pharma AG develops, produces and distributes medical devices and drugs (anti-infectives, vitamins) for regenerative medicine at the Wolhusen and Root sites in central Switzerland. The Swiss company forms part of the Geistlich group which has been in family hands since 1851. Geistlich Pharma and its three business units Geistlich Biomaterials, Geistlich Surgery and Geistlich Medical have ten subsidiaries and global distribution. Some 500 employees work for the company around the world. The company is a world leader in regenerative dentistry through its business unit Geistlich Biomaterials. The ownership structure enables the company to plan long-term and to consistently develop innovative products. Geistlich Pharma AG continuously invests in developing its research and technology and relies on its qualified and specialized employees. Currently Geistlich Pharma is - the global market leader in regenerative dentistry - the leader in biological bone and cartilage regeneration - supplies drugs and medical devices in selected application areas